{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055689","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.527211+00:00","generated_at":"2026-06-02T10:55:55.074611+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CRISPR Therapeutics Q1 net loss widens to $116.6M; cash $2.1B after $280M offering and $200M milestone","bullets":["Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.","Ended March with $2.1B cash; includes $280M February direct offering and $200M CASGEVY milestone from Vertex.","CASGEVY now approved in 5 regions; over 25 ATCs activated globally, multiple patients have cells collected.","Next-gen CAR T CTX112 (CD19) and CTX131 (CD70) trials ongoing; preliminary CTX112 data expected this year.","New in vivo programs CTX340 (hypertension) and CTX450 (porphyria) enter IND-enabling studies; clinical trials targeted for H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055689","json":"https://secwatch.observer/filing/0000950170-24-055689.json","markdown":"https://secwatch.observer/filing/0000950170-24-055689.md","text":"https://secwatch.observer/filing/0000950170-24-055689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/0000950170-24-055689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/crsp-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:55:55.074611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6327aac1dd0e272901fe2bbbb0b67f787f49478","claim":"CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/0000950170-24-055689-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}